	US 11,873,337 B2
	Antibody binding to cell adhesion molecule 3
Nobuaki Takahashi, Tokyo (JP); Ryosuke Nakano, Tokyo (JP); Sayaka Maeda, Tokyo (JP); Takenao Yamada, Tokyo (JP); and Yuji Ito, Kagoshima (JP)
Assigned to KYOWA KIRIN CO., LTD., Tokyo (JP); and KAGOSHIMA UNIVERSITY, Kagoshima (JP)
Appl. No. 17/255,784
Filed by Kyowa Kirin Co., Ltd., Tokyo (JP); and KAGOSHIMA UNIVERSITY, Kagoshima (JP)
PCT Filed Jun. 26, 2019, PCT No. PCT/JP2019/025454 § 371(c)(1), (2) Date Dec. 23, 2020, PCT Pub. No. WO2020/004492, PCT Pub. Date Jan. 2, 2020.
Claims priority of application No. 2018-120477 (JP), filed on Jun. 26, 2018.
Prior Publication US 2021/0147541 A1, May 20, 2021
Int. Cl. C07K 16/28 (2006.01); A61K 39/00 (2006.01)

CPC C07K 16/2803 (2013.01) [A61K 2039/505 (2013.01); C07K 2317/14 (2013.01); C07K 2317/31 (2013.01); C07K 2317/33 (2013.01); C07K 2317/565 (2013.01)]

29 Claims

1. An antibody which binds to cell adhesion molecule 3 (CADM3) or an antibody fragment thereof,

wherein the antibody or the antibody fragment thereof is selected from the group consisting of the following (a) to (t):

(a) an antibody in which the amino acid sequences of complementarity determining regions (CDRs) 1 to 3 of a variable domain of a heavy chain (VH) comprise the amino acid sequences represented by SEQ ID NOS: 23, 24, and 25, respectively, and in which the amino acid sequences of CDR1 to CDR3 of a variable domain of a light chain (VL) comprise the amino acid sequences represented by SEQ ID NOS: 28, 29, and 30, respectively;

(b) an antibody in which the amino acid sequences of CDR1 to CDR3 of VH comprise the amino acid sequences represented by SEQ ID NOS: 33, 34 and 35, respectively, and in which the amino acid sequences of CDR1 to CDR3 of VL comprise the amino acid sequences represented by SEQ ID NOS: 38, 39, and 40, respectively;

(c) an antibody fragment in which the amino acid sequences of CDR1 to CDR3 of a variable domain of a heavy chain of a heavy chain antibody (VHH) comprise the amino acid sequences represented by SEQ ID NOS: 3, 4, and 5, respectively;

(d) an antibody fragment in which the amino acid sequences of CDR1 to CDR3 of VHH comprise the amino acid sequences represented by SEQ ID NOS: 8, 9, and 10, respectively;

(e) an antibody fragment in which the amino acid sequences of CDR1 to CDR3 of VHH comprise the amino acid sequences represented by SEQ ID NOS: 13, 14, and 15, respectively;

(f) an antibody fragment in which the amino acid sequences of CDR1 to CDR3 of VHH comprise the amino acid sequences represented by SEQ ID NOS: 18, 19, and 20, respectively;

(g) an antibody in which the amino acid sequences of CDR1 to CDR3 of VH comprise the amino acid sequences represented by SEQ ID NOS: 89, 90, and 91, respectively, and in which the amino acid sequences of CDR1 to CDR3 of VL comprise the amino acid sequences represented by SEQ ID NOS: 94, 95, and 96, respectively;

(h) an antibody in which the amino acid sequences of CDR1 to CDR3 of VH comprise the amino acid sequences represented by SEQ ID NOS: 99, 100, and 101, respectively, and in which the amino acid sequences of CDR1 to CDR3 of VL comprise the amino acid sequences represented by SEQ ID NOS: 134, 135, and 136, respectively;

(i) an antibody in which the amino acid sequences of CDR1 to CDR3 of VH comprise the amino acid sequences represented by SEQ ID NOS: 104, 105, and 106, respectively, and in which the amino acid sequences of CDR1 to CDR3 of VL comprise the amino acid sequences represented by SEQ ID NOS: 134, 135, and 136, respectively;

(j) an antibody in which the amino acid sequences of CDR1 to CDR3 of VH comprise the amino acid sequences represented by SEQ ID NOS: 109, 110, and 111, respectively, and in which the amino acid sequences of CDR1 to CDR3 of VL comprise the amino acid sequences represented by SEQ ID NOS: 134, 135, and 136, respectively;

(k) an antibody in which the amino acid sequences of CDR1 to CDR3 of VH comprise the amino acid sequences represented by SEQ ID NOS: 114, 115, and, 116, respectively, and in which the amino acid sequences of CDR1 to CDR3 of VL comprise the amino acid sequences represented by SEQ ID NOS: 134, 135, and 136, respectively;

(l) an antibody in which the amino acid sequences of CDR1 to CDR3 of VH comprise the amino acid sequences represented by SEQ ID NOS: 119, 120, and 121, respectively, and in which the amino acid sequences of CDR1 to CDR3 of VL comprise the amino acid sequences represented by SEQ ID NOS: 134, 135, and 136, respectively;

(m) an antibody in which the amino acid sequences of CDR1 to CDR3 of VH comprise the amino acid sequences represented by SEQ ID NOS: 124, 125, and 126, respectively, and in which the amino acid sequences of CDR1 to CDR3 of VL comprise the amino acid sequences represented by SEQ ID NOS: 134, 135, and 136, respectively;

(n) an antibody in which the amino acid sequences of CDR1 to CDR3 of VH comprise the amino acid sequences represented by SEQ ID NOS: 129, 130, and 131, respectively, and in which the amino acid sequences of CDR1 to CDR3 of VL comprise the amino acid sequences represented by SEQ ID NOS: 134, 135, and 136, respectively;

(o) an antibody in which the amino acid sequences of CDR1 to CDR3 of VH comprise the amino acid sequences represented by SEQ ID NOS: 139, 140, and 141, respectively, and in which the amino acid sequences of CDR1 to CDR3 of VL comprise the amino acid sequences represented by SEQ ID NOS: 164, 165, and 166, respectively;

(p) an antibody in which the amino acid sequences of CDR1 to CDR3 of VH comprise the amino acid sequences represented by SEQ ID NOS: 144, 145, and 146, respectively, and in which the amino acid sequences of CDR1 to CDR3 of VL comprise the amino acid sequences represented by SEQ ID NOS: 164, 165, and 166, respectively;

(q) an antibody in which the amino acid sequences of CDR1 to CDR3 of VH comprise the amino acid sequences represented by SEQ ID NOS: 149, 150, and 151, respectively, and in which the amino acid sequences of CDR1 to CDR3 of VL comprise the amino acid sequences represented by SEQ ID NOS: 164, 165, and 166, respectively;

(r) an antibody in which the amino acid sequences of CDR1 to CDR3 of VH comprise the amino acid sequences represented by SEQ ID NOS: 154, 155, and 156, respectively, and in which the amino acid sequences of CDR1 to CDR3 of VL comprise the amino acid sequences represented by SEQ ID NOS: 164, 165, and 166, respectively;

(s) an antibody in which the amino acid sequences of CDR1 to CDR3 of VH comprise the amino acid sequences represented by SEQ ID NOS: 159, 160, and 161, respectively, and in which the amino acid sequences of CDR1 to CDR3 of VL comprise the amino acid sequences represented by SEQ ID NOS: 164, 165, and 166, respectively; and

(t) an antibody in which the amino acid sequences of CDR1 to CDR3 of VH comprise the amino acid sequences represented by SEQ ID NOS: 169, 170, and 171, respectively, and in which the amino acid sequences of CDR1 to CDR3 of VL comprise the amino acid sequences represented by SEQ ID NOS: 174, 175, and 176, respectively.